Amgen reports profit growth amid regulatory challenges
Amgen reported third quarter 2026 quarterly revenue growth of 8.5% to $10.4 billion and net income growth of 20.1% to $3.9 billion. The report also details new regulatory challenges and clinical trial results shaping the operating environment for shareholders.
Key points
- In its third quarter 2026 financial report, the company confirmed the negative impact of Inflation Reduction Act (IRA) provisions and expanded use of the 340B program on its performance.
- Amgen announced positive Phase 3 results for several products.
- On November 6, 2026, directors Michael V. Drake, David W. Gibbs, Charles M. Holley, and Omar Ishrak received company shares as compensation.
Financial results and regulatory pressure
In its third quarter 2026 financial report, the company confirmed the negative impact of Inflation Reduction Act (IRA) provisions and expanded use of the 340B program on its performance. CMS selected ENBREL and Otezla for Medicare price setting beginning in 2026 and 2027, respectively. In response, the company will participate in a one-year 340B rebate pilot program starting in January 2027, though it notes this may not fully offset the effects of improper discount utilization.
Quarter vs the same quarter a year earlier
Clinical achievements and safety
Amgen announced positive Phase 3 results for several products. TEZSPIRE demonstrated improvement in patients with eosinophilic esophagitis, Repatha received an expanded indication in Europe to reduce cardiovascular risk, and the DeLLphi-305 study confirmed improved overall survival using IMDELLTRA/IMDYLLTRA.
The company continues to face cybersecurity threats, including incidents affecting third-party service providers. Amgen noted that such cases, including an incident reported in July 2026, can lead to unauthorized data access.
Director transactions
On November 6, 2026, directors Michael V. Drake, David W. Gibbs, Charles M. Holley, and Omar Ishrak received company shares as compensation. The number of shares acquired was: 114.0263 for Drake, 278 for Gibbs, 184.614 for Holley, and 152.0351 for Ishrak.
What to watch
Investors should monitor the final legal status of the Upper Payment Limit (UPL) for ENBREL in Colorado, as its implementation is currently preliminarily enjoined by a court. It is also important to evaluate the effectiveness of the 340B rebate pilot program starting in January 2027 in mitigating financial losses from duplicate discounts.
Original sources
- 10-Q risk factors compared with the 10-Q filing, August 5, 2026
- financial data (XBRL)
- 4 filing, November 9, 2026
- 4 filing, November 9, 2026
- 4 filing, November 9, 2026
- 4 filing, November 9, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Amgen
A notification in your browser or on your phone when we publish about Amgen. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
